We are hiring! Reach out to learn more ->

Making transformative medicine accessible to every patient

With subscription-based access to gene therapy

Learn More

The Problem

More transformative medicines are reaching the market, but the payment solution is not yet in place.

Gene therapies are changing the lives of patients and families devastated by rare diseases. These medicines offer the remarkable hope of a life-saving, potentially curative treatment for previously untreatable diseases. And with 2,500+ trials in the pipeline and a growth rate of 25% per year, this industry is poised to revolutionize medicine.

However, these high-cost, ultra-rare therapies also pose unique challenges for payers across the world when it comes to coverage and reimbursement. Without a payment solution as innovative as the cures themselves, we anticipate patient access becoming a structural issue within 2-3 years, with the burden ultimately falling upon patients and families.

Drugs approved by 2025
Price for a single treatment
Annual treatment spend by 2030

Our Solution

Quantile Health is solving the problem of patient access to gene therapies by creating a reimbursement platform that allows payers of all sizes to directly enter into subscription-based access agreements with drug manufacturers
Patients and Families
Gene therapies are savings lives, but limited to those who can afford them
New gene therapies pose significant pricing risk to health plans that existing actuarial methods aren't equipped to handle
Getting payers to cover a new therapy is the most time-intensive and frictional part of a treatment's go-to market process

[SOURCE] Wong, Chi Heem, Dexin Li, Nina Wang, Jonathan Gruber, Rena Conti, and Andrew W. Lo (2020), Estimating the Financial Impact of Gene Therapy (Preprint), medRxiv 2020.10.27.20220871, https://doi.org/10.1101/2020.10 .27.20220871.

Meet the Team

Our founding team is a group of healthcare experts, financial engineers, data scientists and leaders in industry.

Yutong Sun
Co-Founder & CEO
Former Lead Data Scientist, Oscar Health
Peter D. Hancock
Former President and CEO, AIG and Former CFO, J.P. Morgan
Andrew W. Lo
Charles E. and Susan T. Harris Professor of Finance at the MIT Sloan School of Management
Jonathan H. Gruber
Chief Policy Officer
Ford Professor of Economics at MIT

Our Advisors

Rena Conti
Associate Professor, Markets, Public Policy, and Law at Boston University
Joel Klein
Former Assistant Attorney General of the United States
Sid Sankaran
Former Chairman and CEO, SiriusPoint
Mario Schlosser
Co-founder and Former CEO, Oscar Health
Frank Zhang
Former Head of Commercial, Uniqure
Alison Finger
Former Chief Commercial Officer, bluebird bio


Quantile's insights on the social and economic impact of gene therapies

Read More